Scientists Uncover New Cardiovascular Benefits of Popular Weight Loss Drugs
New studies in JACC highlight improvements in cardiac structure and function among CABG patients, as well as changes in cardiac risk biomarkers linked to lifestyle interventions.
New research published in JACC, the flagship journal of the American College of Cardiology, and presented at the American Heart Association’s 2024 Scientific Sessions highlights that widely used anti-obesity medications offer cardiovascular benefits that extend beyond weight loss. JACC is publishing two secondary analyses on the impact of GLP-1 medications in improving cardiac structure and function in heart failure patients and cardiovascular outcomes in those who previously had cardiac bypass surgery, plus a new analysis of a lifestyle intervention trial showing that cardiac risk biomarkers change with weight loss.
“These studies reinforce the potential of GLP-1-based therapies not only to aid in weight loss but also to transform cardiac health, offering hope for patients living with obesity and cardiovascular disease,” said Harlan M. Krumholz, MD, SM, editor-in-chief of JACC and the Harold H. Hines Jr Professor of Medicine at Yale University School of Medicine. “As the science evolves, we are achieving a deeper understanding of how weight loss, and treatment with these medications, can improve outcomes across diverse patient populations with obesity.”………..click here to the original story.
